Pharma & Healthcare
Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Research Report 2024
- Feb 19, 24
- ID: 53647
- Pages: 75
- Figures: 146
- Views: 18
Kidney cancer/ renal cell carcinoma (RCC) is among ten most commonly observed cancer these days. It is sixth common cancer observed in men and it is the tenth most common cause of cancer for women.
The global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market was valued at US$ 5107.4 million in 2023 and is anticipated to reach US$ 6449.9 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs.
Report Scope
The Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Active Biotech Ab
Amgen
Bayer AG
Cipla Limited
Roche Holding AG
Glaxosmithkline Plc
Novartis Ag
Pfizer, Inc.
Segment by Type
Afinitor (Everolimus)
Avastin (Bevacizumab)
Cabomety (Cabozantinib)
Inlyta (Axitinib)
Nexavar (Sorafenib)
Proleukin (Aldesleukin)
Torisel (Temsirolimus)
Sutent (Sunitinib)
Votrient (Pazopanib)
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market was valued at US$ 5107.4 million in 2023 and is anticipated to reach US$ 6449.9 million by 2030, witnessing a CAGR of 3.3% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs.
Report Scope
The Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Active Biotech Ab
Amgen
Bayer AG
Cipla Limited
Roche Holding AG
Glaxosmithkline Plc
Novartis Ag
Pfizer, Inc.
Segment by Type
Afinitor (Everolimus)
Avastin (Bevacizumab)
Cabomety (Cabozantinib)
Inlyta (Axitinib)
Nexavar (Sorafenib)
Proleukin (Aldesleukin)
Torisel (Temsirolimus)
Sutent (Sunitinib)
Votrient (Pazopanib)
Segment by Application
Hospitals
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Afinitor (Everolimus)
1.2.3 Avastin (Bevacizumab)
1.2.4 Cabomety (Cabozantinib)
1.2.5 Inlyta (Axitinib)
1.2.6 Nexavar (Sorafenib)
1.2.7 Proleukin (Aldesleukin)
1.2.8 Torisel (Temsirolimus)
1.2.9 Sutent (Sunitinib)
1.2.10 Votrient (Pazopanib)
1.3 Market by Application
1.3.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Perspective (2019-2030)
2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Growth Trends by Region
2.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Region (2019-2024)
2.2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Region (2025-2030)
2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Dynamics
2.3.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Industry Trends
2.3.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers
2.3.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Challenges
2.3.4 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue
3.1.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue (2019-2024)
3.1.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue
3.4 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio
3.4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2023
3.5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players Head office and Area Served
3.6 Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service
3.7 Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Breakdown Data by Type
4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Type (2019-2024)
4.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Type (2025-2030)
5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Breakdown Data by Application
5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Application (2019-2024)
5.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
6.2 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024)
6.4 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
7.2 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024)
7.4 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
8.2 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
9.2 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024)
9.4 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
10.2 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Active Biotech Ab
11.1.1 Active Biotech Ab Company Detail
11.1.2 Active Biotech Ab Business Overview
11.1.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.1.4 Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.1.5 Active Biotech Ab Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.2.4 Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 Bayer AG
11.3.1 Bayer AG Company Detail
11.3.2 Bayer AG Business Overview
11.3.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.3.4 Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.3.5 Bayer AG Recent Development
11.4 Cipla Limited
11.4.1 Cipla Limited Company Detail
11.4.2 Cipla Limited Business Overview
11.4.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.4.4 Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.4.5 Cipla Limited Recent Development
11.5 Roche Holding AG
11.5.1 Roche Holding AG Company Detail
11.5.2 Roche Holding AG Business Overview
11.5.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.5.4 Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.5.5 Roche Holding AG Recent Development
11.6 Glaxosmithkline Plc
11.6.1 Glaxosmithkline Plc Company Detail
11.6.2 Glaxosmithkline Plc Business Overview
11.6.3 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.6.4 Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.6.5 Glaxosmithkline Plc Recent Development
11.7 Novartis Ag
11.7.1 Novartis Ag Company Detail
11.7.2 Novartis Ag Business Overview
11.7.3 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.7.4 Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.7.5 Novartis Ag Recent Development
11.8 Pfizer, Inc.
11.8.1 Pfizer, Inc. Company Detail
11.8.2 Pfizer, Inc. Business Overview
11.8.3 Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.8.4 Pfizer, Inc. Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.8.5 Pfizer, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Afinitor (Everolimus)
1.2.3 Avastin (Bevacizumab)
1.2.4 Cabomety (Cabozantinib)
1.2.5 Inlyta (Axitinib)
1.2.6 Nexavar (Sorafenib)
1.2.7 Proleukin (Aldesleukin)
1.2.8 Torisel (Temsirolimus)
1.2.9 Sutent (Sunitinib)
1.2.10 Votrient (Pazopanib)
1.3 Market by Application
1.3.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Perspective (2019-2030)
2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Growth Trends by Region
2.2.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Region (2019-2024)
2.2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Region (2025-2030)
2.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Dynamics
2.3.1 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Industry Trends
2.3.2 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers
2.3.3 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Challenges
2.3.4 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue
3.1.1 Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Revenue (2019-2024)
3.1.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue
3.4 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio
3.4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2023
3.5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Key Players Head office and Area Served
3.6 Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service
3.7 Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Breakdown Data by Type
4.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Type (2019-2024)
4.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Type (2025-2030)
5 Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Breakdown Data by Application
5.1 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Historic Market Size by Application (2019-2024)
5.2 Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
6.2 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024)
6.4 North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
7.2 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024)
7.4 Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
8.2 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
9.2 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024)
9.4 Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (2019-2030)
10.2 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Active Biotech Ab
11.1.1 Active Biotech Ab Company Detail
11.1.2 Active Biotech Ab Business Overview
11.1.3 Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.1.4 Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.1.5 Active Biotech Ab Recent Development
11.2 Amgen
11.2.1 Amgen Company Detail
11.2.2 Amgen Business Overview
11.2.3 Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.2.4 Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.2.5 Amgen Recent Development
11.3 Bayer AG
11.3.1 Bayer AG Company Detail
11.3.2 Bayer AG Business Overview
11.3.3 Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.3.4 Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.3.5 Bayer AG Recent Development
11.4 Cipla Limited
11.4.1 Cipla Limited Company Detail
11.4.2 Cipla Limited Business Overview
11.4.3 Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.4.4 Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.4.5 Cipla Limited Recent Development
11.5 Roche Holding AG
11.5.1 Roche Holding AG Company Detail
11.5.2 Roche Holding AG Business Overview
11.5.3 Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.5.4 Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.5.5 Roche Holding AG Recent Development
11.6 Glaxosmithkline Plc
11.6.1 Glaxosmithkline Plc Company Detail
11.6.2 Glaxosmithkline Plc Business Overview
11.6.3 Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.6.4 Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.6.5 Glaxosmithkline Plc Recent Development
11.7 Novartis Ag
11.7.1 Novartis Ag Company Detail
11.7.2 Novartis Ag Business Overview
11.7.3 Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.7.4 Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.7.5 Novartis Ag Recent Development
11.8 Pfizer, Inc.
11.8.1 Pfizer, Inc. Company Detail
11.8.2 Pfizer, Inc. Business Overview
11.8.3 Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Introduction
11.8.4 Pfizer, Inc. Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
11.8.5 Pfizer, Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Afinitor (Everolimus)
Table 3. Key Players of Avastin (Bevacizumab)
Table 4. Key Players of Cabomety (Cabozantinib)
Table 5. Key Players of Inlyta (Axitinib)
Table 6. Key Players of Nexavar (Sorafenib)
Table 7. Key Players of Proleukin (Aldesleukin)
Table 8. Key Players of Torisel (Temsirolimus)
Table 9. Key Players of Sutent (Sunitinib)
Table 10. Key Players of Votrient (Pazopanib)
Table 11. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 12. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 13. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 14. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region (2019-2024)
Table 15. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 16. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region (2025-2030)
Table 17. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Trends
Table 18. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers
Table 19. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Challenges
Table 20. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints
Table 21. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 22. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players (2019-2024)
Table 23. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2023)
Table 24. Ranking of Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies by Revenue (US$ Million) in 2023
Table 25. Global 5 Largest Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service
Table 28. Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 31. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2019-2024)
Table 32. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 33. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2025-2030)
Table 34. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 35. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Application (2019-2024)
Table 36. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 37. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Application (2025-2030)
Table 38. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 40. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 41. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 43. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 44. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 45. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 46. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 47. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 49. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 50. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 51. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 52. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 53. Active Biotech Ab Company Detail
Table 54. Active Biotech Ab Business Overview
Table 55. Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 56. Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 57. Active Biotech Ab Recent Development
Table 58. Amgen Company Detail
Table 59. Amgen Business Overview
Table 60. Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 61. Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 62. Amgen Recent Development
Table 63. Bayer AG Company Detail
Table 64. Bayer AG Business Overview
Table 65. Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 66. Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 67. Bayer AG Recent Development
Table 68. Cipla Limited Company Detail
Table 69. Cipla Limited Business Overview
Table 70. Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 71. Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 72. Cipla Limited Recent Development
Table 73. Roche Holding AG Company Detail
Table 74. Roche Holding AG Business Overview
Table 75. Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 76. Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 77. Roche Holding AG Recent Development
Table 78. Glaxosmithkline Plc Company Detail
Table 79. Glaxosmithkline Plc Business Overview
Table 80. Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 81. Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 82. Glaxosmithkline Plc Recent Development
Table 83. Novartis Ag Company Detail
Table 84. Novartis Ag Business Overview
Table 85. Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 86. Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 87. Novartis Ag Recent Development
Table 88. Pfizer, Inc. Company Detail
Table 89. Pfizer, Inc. Business Overview
Table 90. Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 91. Pfizer, Inc. Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 92. Pfizer, Inc. Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type: 2023 VS 2030
Figure 3. Afinitor (Everolimus) Features
Figure 4. Avastin (Bevacizumab) Features
Figure 5. Cabomety (Cabozantinib) Features
Figure 6. Inlyta (Axitinib) Features
Figure 7. Nexavar (Sorafenib) Features
Figure 8. Proleukin (Aldesleukin) Features
Figure 9. Torisel (Temsirolimus) Features
Figure 10. Sutent (Sunitinib) Features
Figure 11. Votrient (Pazopanib) Features
Figure 12. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 13. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application: 2023 VS 2030
Figure 14. Hospitals Case Studies
Figure 15. Clinic Case Studies
Figure 16. Others Case Studies
Figure 17. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Report Years Considered
Figure 18. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 19. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 20. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region: 2023 VS 2030
Figure 21. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players in 2023
Figure 22. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2023)
Figure 23. The Top 10 and 5 Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2023
Figure 24. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2019-2030)
Figure 26. United States Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Canada Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2019-2030)
Figure 30. Germany Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. France Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. U.K. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Italy Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Russia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Nordic Countries Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region (2019-2030)
Figure 38. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Australia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2019-2030)
Figure 46. Mexico Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Brazil Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2019-2030)
Figure 50. Turkey Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Active Biotech Ab Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 53. Amgen Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 54. Bayer AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 55. Cipla Limited Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 56. Roche Holding AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 57. Glaxosmithkline Plc Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 58. Novartis Ag Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 59. Pfizer, Inc. Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Afinitor (Everolimus)
Table 3. Key Players of Avastin (Bevacizumab)
Table 4. Key Players of Cabomety (Cabozantinib)
Table 5. Key Players of Inlyta (Axitinib)
Table 6. Key Players of Nexavar (Sorafenib)
Table 7. Key Players of Proleukin (Aldesleukin)
Table 8. Key Players of Torisel (Temsirolimus)
Table 9. Key Players of Sutent (Sunitinib)
Table 10. Key Players of Votrient (Pazopanib)
Table 11. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 12. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 13. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 14. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region (2019-2024)
Table 15. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 16. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region (2025-2030)
Table 17. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Trends
Table 18. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Drivers
Table 19. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Challenges
Table 20. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Restraints
Table 21. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 22. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players (2019-2024)
Table 23. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2023)
Table 24. Ranking of Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Companies by Revenue (US$ Million) in 2023
Table 25. Global 5 Largest Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 26. Key Players Headquarters and Area Served
Table 27. Key Players Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product Solution and Service
Table 28. Date of Enter into Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market
Table 29. Mergers & Acquisitions, Expansion Plans
Table 30. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 31. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2019-2024)
Table 32. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 33. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Type (2025-2030)
Table 34. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 35. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Application (2019-2024)
Table 36. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 37. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue Market Share by Application (2025-2030)
Table 38. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 39. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 40. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 41. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 42. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 43. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 44. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 45. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 46. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 47. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 48. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 49. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 50. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 51. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 52. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 53. Active Biotech Ab Company Detail
Table 54. Active Biotech Ab Business Overview
Table 55. Active Biotech Ab Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 56. Active Biotech Ab Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 57. Active Biotech Ab Recent Development
Table 58. Amgen Company Detail
Table 59. Amgen Business Overview
Table 60. Amgen Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 61. Amgen Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 62. Amgen Recent Development
Table 63. Bayer AG Company Detail
Table 64. Bayer AG Business Overview
Table 65. Bayer AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 66. Bayer AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 67. Bayer AG Recent Development
Table 68. Cipla Limited Company Detail
Table 69. Cipla Limited Business Overview
Table 70. Cipla Limited Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 71. Cipla Limited Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 72. Cipla Limited Recent Development
Table 73. Roche Holding AG Company Detail
Table 74. Roche Holding AG Business Overview
Table 75. Roche Holding AG Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 76. Roche Holding AG Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 77. Roche Holding AG Recent Development
Table 78. Glaxosmithkline Plc Company Detail
Table 79. Glaxosmithkline Plc Business Overview
Table 80. Glaxosmithkline Plc Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 81. Glaxosmithkline Plc Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 82. Glaxosmithkline Plc Recent Development
Table 83. Novartis Ag Company Detail
Table 84. Novartis Ag Business Overview
Table 85. Novartis Ag Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 86. Novartis Ag Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 87. Novartis Ag Recent Development
Table 88. Pfizer, Inc. Company Detail
Table 89. Pfizer, Inc. Business Overview
Table 90. Pfizer, Inc. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Product
Table 91. Pfizer, Inc. Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024) & (US$ Million)
Table 92. Pfizer, Inc. Recent Development
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Type: 2023 VS 2030
Figure 3. Afinitor (Everolimus) Features
Figure 4. Avastin (Bevacizumab) Features
Figure 5. Cabomety (Cabozantinib) Features
Figure 6. Inlyta (Axitinib) Features
Figure 7. Nexavar (Sorafenib) Features
Figure 8. Proleukin (Aldesleukin) Features
Figure 9. Torisel (Temsirolimus) Features
Figure 10. Sutent (Sunitinib) Features
Figure 11. Votrient (Pazopanib) Features
Figure 12. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 13. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Application: 2023 VS 2030
Figure 14. Hospitals Case Studies
Figure 15. Clinic Case Studies
Figure 16. Others Case Studies
Figure 17. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Report Years Considered
Figure 18. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 19. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 20. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region: 2023 VS 2030
Figure 21. Global Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Players in 2023
Figure 22. Global Top Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs as of 2023)
Figure 23. The Top 10 and 5 Players Market Share by Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Revenue in 2023
Figure 24. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. North America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2019-2030)
Figure 26. United States Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Canada Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Europe Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2019-2030)
Figure 30. Germany Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. France Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. U.K. Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Italy Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Russia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Nordic Countries Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Asia-Pacific Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Region (2019-2030)
Figure 38. China Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Japan Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. South Korea Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Southeast Asia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. India Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Australia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Latin America Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2019-2030)
Figure 46. Mexico Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. Brazil Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. Middle East & Africa Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Share by Country (2019-2030)
Figure 50. Turkey Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 51. Saudi Arabia Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 52. Active Biotech Ab Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 53. Amgen Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 54. Bayer AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 55. Cipla Limited Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 56. Roche Holding AG Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 57. Glaxosmithkline Plc Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 58. Novartis Ag Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 59. Pfizer, Inc. Revenue Growth Rate in Kidney Cancer and Renal Cell Carcinoma (RCC) Drugs Business (2019-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Food Grade FIBC Bulk Bags Market Research Report 2025
Jan 09, 25
Global Standard FIBC Market Research Report 2025
Jan 09, 25
Global Mammoplasty Retractors Market Research Report 2025
Jan 09, 25
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232